{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:37:21Z","timestamp":1792597041451,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106844","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:06:57Z","timestamp":1784045217000},"page":"106844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-1292","authenticated-orcid":false,"given":"Marco","family":"Zuin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Vedovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-5276","authenticated-orcid":false,"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106844_bib1","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106844_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: the when, how and why","volume":"28","author":"Fernandes","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rpth.2026.106844_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106844_bib4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.rpth.2026.106844_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.rpth.2026.106844_bib6","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106844_bib7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","article-title":"Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism","volume":"43","author":"Girardi","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2026.106844_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11606-014-2993-8","article-title":"Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism","volume":"30","author":"Leiss","year":"2015","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.rpth.2026.106844_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.102177","article-title":"Systemic treatment among frail older patients with cancer: an observational cohort","volume":"16","author":"Doublet","year":"2025","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.rpth.2026.106844_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rpth.2026.106844_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106844_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2019.06.015","article-title":"Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)","volume":"118","author":"Gezelius","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rpth.2026.106844_bib13","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106844_bib14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106844_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106844_bib16","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106844_bib17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106844_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2026.106844_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11606-021-06999-9","article-title":"The Fragility Index for assessing the robustness of the statistically significant results of experimental clinical studies","volume":"37","author":"Ho","year":"2022","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.rpth.2026.106844_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamasurg.2018.4318","article-title":"The Fragility Index in randomized clinical trials as a means of optimizing patient care","volume":"154","author":"Tignanelli","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.rpth.2026.106844_bib21","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2026.106844_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jclinepi.2013.10.019","article-title":"The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index","volume":"67","author":"Walsh","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rpth.2026.106844_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005755","article-title":"Fragility index in cardiovascular randomized controlled trials","volume":"12","author":"Khan","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.rpth.2026.106844_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.semtcvs.2022.05.010","article-title":"Reverse fragility index in negative cardiac procedural randomized controlled trials","volume":"35","author":"Dhingra","year":"2023","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rpth.2026.106844_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jclinepi.2019.03.012","article-title":"The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses","volume":"111","author":"Atal","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rpth.2026.106844_bib26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106844_bib27","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11912-023-01428-y","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism","volume":"25","author":"Masini","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.rpth.2026.106844_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jclinepi.2019.09.029","article-title":"The fragility index of practice changing clinical trials is low and highly correlated with P-values","volume":"119","author":"Niforatos","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rpth.2026.106844_bib29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"Cancer-associated venous thromboembolic disease, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Streiff","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2026.106844_bib30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"Schaefer","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106844_bib31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","article-title":"Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.rpth.2026.106844_bib32","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2026.106844_bib33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:53:47Z","timestamp":1790164427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035028"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106844","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106844"}}